Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Kretschmer

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Cardiovascular Pharmacology|July 6, 2019
Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor AntagonistPeter Kolkhof, Elisabeth Pook, Mira Pavkovic, et al.
Plos One|April 13, 2018
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast mediumLyubov Chaykovska, Fabian Heunisch, Gina von Einem, et al.
Plos One|August 18, 2012
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockadeIna M Ott, Markus L Alter, Karoline von Websky, et al.
American Journal of Nephrology|December 20, 2011
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcificationSilvia Salem, Heike Bruck, Ferdinand H Bahlmann, et al.
International Journal of Cardiology|May 4, 2016
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in miceKabita Pradhan, Akylbek Sydykov, Xia Tian, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 22, 2021
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney diseaseAgnès Bénardeau, Antje Kahnert, Tibor Schomber, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 2, 2011
Angioprotectin: an angiotensin II-like peptide causing vasodilatory effectsVera Jankowski, Markus Tölle, Robson A S Santos, et al.
JCI Insight|February 23, 2018
Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fractionNicola Wilck, Lajos Markó, András Balogh, et al.
Drug Discovery Today|May 17, 2011
A generic operational strategy to qualify translational safety biomarkersKatja Matheis, David Laurie, Christiane Andriamandroso, et al.
Journal of Medicinal Chemistry|May 31, 2017
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart FailureMarkus Follmann, Jens Ackerstaff, Gorden Redlich, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Cardiovascular Pharmacology|July 6, 2019
Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor AntagonistPeter Kolkhof, Elisabeth Pook, Mira Pavkovic, et al.
Plos One|April 13, 2018
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast mediumLyubov Chaykovska, Fabian Heunisch, Gina von Einem, et al.
Plos One|August 18, 2012
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockadeIna M Ott, Markus L Alter, Karoline von Websky, et al.
American Journal of Nephrology|December 20, 2011
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcificationSilvia Salem, Heike Bruck, Ferdinand H Bahlmann, et al.
International Journal of Cardiology|May 4, 2016
Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in miceKabita Pradhan, Akylbek Sydykov, Xia Tian, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 22, 2021
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney diseaseAgnès Bénardeau, Antje Kahnert, Tibor Schomber, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 2, 2011
Angioprotectin: an angiotensin II-like peptide causing vasodilatory effectsVera Jankowski, Markus Tölle, Robson A S Santos, et al.
JCI Insight|February 23, 2018
Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fractionNicola Wilck, Lajos Markó, András Balogh, et al.
Drug Discovery Today|May 17, 2011
A generic operational strategy to qualify translational safety biomarkersKatja Matheis, David Laurie, Christiane Andriamandroso, et al.
Journal of Medicinal Chemistry|May 31, 2017
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart FailureMarkus Follmann, Jens Ackerstaff, Gorden Redlich, et al.
Pageof 3